351 related articles for article (PubMed ID: 31800076)
1. Hyperkalemia in patients with chronic renal failure.
Seliger SL
Nephrol Dial Transplant; 2019 Dec; 34(Suppl 3):iii12-iii18. PubMed ID: 31800076
[TBL] [Abstract][Full Text] [Related]
2. Revisiting RAAS blockade in CKD with newer potassium-binding drugs.
Georgianos PI; Agarwal R
Kidney Int; 2018 Feb; 93(2):325-334. PubMed ID: 29276100
[TBL] [Abstract][Full Text] [Related]
3. Pivotal clinical trials, meta-analyses and current guidelines in the treatment of hyperkalemia.
Bianchi S; Regolisti G
Nephrol Dial Transplant; 2019 Dec; 34(Suppl 3):iii51-iii61. PubMed ID: 31800075
[TBL] [Abstract][Full Text] [Related]
4. New Therapeutic Approaches for the Treatment of Hyperkalemia in Patients Treated with Renin-Angiotensin-Aldosterone System Inhibitors.
Tamargo J; Caballero R; Delpón E
Cardiovasc Drugs Ther; 2018 Feb; 32(1):99-119. PubMed ID: 29372448
[TBL] [Abstract][Full Text] [Related]
5. Patiromer: a clinical review.
Montaperto AG; Gandhi MA; Gashlin LZ; Symoniak MR
Curr Med Res Opin; 2016; 32(1):155-64. PubMed ID: 26456884
[TBL] [Abstract][Full Text] [Related]
6. The frequency of hyperkalemia and its significance in chronic kidney disease.
Einhorn LM; Zhan M; Hsu VD; Walker LD; Moen MF; Seliger SL; Weir MR; Fink JC
Arch Intern Med; 2009 Jun; 169(12):1156-62. PubMed ID: 19546417
[TBL] [Abstract][Full Text] [Related]
7. An evaluation of sodium zirconium cyclosilicate as a treatment option for hyperkalemia.
Takkar C; Nassar T; Qunibi W
Expert Opin Pharmacother; 2021 Jan; 22(1):19-28. PubMed ID: 32892634
[TBL] [Abstract][Full Text] [Related]
8. Association of Changes in Creatinine and Potassium Levels After Initiation of Renin Angiotensin Aldosterone System Inhibitors With Emergency Department Visits, Hospitalizations, and Mortality in Individuals With Chronic Kidney Disease.
Garlo KG; Bates DW; Seger DL; Fiskio JM; Charytan DM
JAMA Netw Open; 2018 Nov; 1(7):e183874. PubMed ID: 30646338
[TBL] [Abstract][Full Text] [Related]
9. [Hyperkalemia as a limiting factor in the use of drugs that block the Renin Angiotensin Aldosterone System (RAAS)].
Santoro A; Mandreoli M
G Ital Nefrol; 2018 May; 35(3):. PubMed ID: 29786183
[TBL] [Abstract][Full Text] [Related]
10. Potassium Binders for Hyperkalemia in Chronic Kidney Disease-Diet, Renin-Angiotensin-Aldosterone System Inhibitor Therapy, and Hemodialysis.
Palmer BF
Mayo Clin Proc; 2020 Feb; 95(2):339-354. PubMed ID: 31668450
[TBL] [Abstract][Full Text] [Related]
11. Potassium-Binding Agents to Facilitate Renin-Angiotensin-Aldosterone System Inhibitor Therapy.
Schaefer JA; Gales MA
Ann Pharmacother; 2016 Jun; 50(6):502-10. PubMed ID: 27009290
[TBL] [Abstract][Full Text] [Related]
12. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial.
Bakris GL; Pitt B; Weir MR; Freeman MW; Mayo MR; Garza D; Stasiv Y; Zawadzki R; Berman L; Bushinsky DA;
JAMA; 2015 Jul; 314(2):151-61. PubMed ID: 26172895
[TBL] [Abstract][Full Text] [Related]
13. Hyperkalemia in chronic heart failure with renal dysfunction or diabetes mellitus: Results from the TREAT HF study.
Murat S; Kaya H; Çavuşoğlu Y; Yılmaz MB
Turk Kardiyol Dern Ars; 2021 Apr; 49(3):198-205. PubMed ID: 33847269
[TBL] [Abstract][Full Text] [Related]
14. Advances in treatment of hyperkalemia in chronic kidney disease.
Sarafidis PA; Georgianos PI; Bakris GL
Expert Opin Pharmacother; 2015; 16(14):2205-15. PubMed ID: 26330193
[TBL] [Abstract][Full Text] [Related]
15. Serum potassium in stage 5 CKD patients on their first presentation in a dialysis service of a county hospital in western Romania.
Gluhovschi G; Mateş A; Gluhovschi C; Golea O; Gădălean F; Somai M; Ene I; Petrica L; Velciov S
Rom J Intern Med; 2014; 52(1):30-8. PubMed ID: 25000676
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic Treatment of Chronic Hyperkalemia in Patients with Chronic Kidney Disease.
Kim GH
Electrolyte Blood Press; 2019 Jun; 17(1):1-6. PubMed ID: 31338108
[TBL] [Abstract][Full Text] [Related]
17. Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study.
Spinowitz BS; Fishbane S; Pergola PE; Roger SD; Lerma EV; Butler J; von Haehling S; Adler SH; Zhao J; Singh B; Lavin PT; McCullough PA; Kosiborod M; Packham DK;
Clin J Am Soc Nephrol; 2019 Jun; 14(6):798-809. PubMed ID: 31110051
[TBL] [Abstract][Full Text] [Related]
18. Sodium zirconium cyclosilicate: a new potassium binder for the treatment of hyperkalemia.
Cases A; Gorriz JL
Drugs Today (Barc); 2018 Oct; 54(10):601-613. PubMed ID: 30398481
[TBL] [Abstract][Full Text] [Related]
19. Sodium zirconium cyclosilicate for the management of chronic hyperkalemia in kidney disease, a novel agent.
Rastogi A; Hanna RM; Mkrttchyan A; Khalid M; Yaqoob S; Shaffer K; Dhawan P; Nobakht N; Kamgar M; Goshtaseb R; Sarmosyan K; Gnarini M; Wassef O; Lerma E
Expert Rev Clin Pharmacol; 2021 Sep; 14(9):1055-1064. PubMed ID: 34227913
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic update on oral potassium exchange resin use in chronic kidney disease patients: a systematic review of randomized controlled clinical trials.
Gruver J; Al-Makki A; Shepler B
J Pharm Pharm Sci; 2023; 26():11892. PubMed ID: 38173862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
